AMGN logo Amgen +
Amgen
+
Revenue breakdown by Products & Services
Revenue breakdown by Geography

Amgen's Revenue by Segment

In fiscal year 2025, Amgen's revenue by segment (products & services) are as follows:

  • Aranesp: $1.39 B
  • BLINCYTO: $1.56 B
  • ENBREL: $2.23 B
  • EVENITY: $2.10 B
  • KRYSTEXXA: $1.34 B
  • Nplate: $1.52 B
  • Otezla: $2.27 B
  • Other Products: $7.26 B
  • Product and Service, Other: $1.60 B
  • Prolia: $4.41 B
  • Repatha: $3.02 B
  • TEPEZZA: $1.90 B
  • TEZSPIRE: $1.48 B
  • Vectibix: $1.18 B
  • XGEVA: $2.08 B

Learn more about Amgen’s Revenue by Geography

Check out competitors to Amgen in a side-by-side comparison.

Explore additional financial metrics for Amgen.

Continue reading...

The above chart shows Amgen's revenue percentage share by segment (products and services).

In fiscal year 2023, Amgen's revenue by segment is as follows:

  • Aranesp generated $1.36 B in revenue, representing 4.83% of its total revenue.
  • BLINCYTO generated $861.00 M in revenue, representing 3.05% of its total revenue.
  • ENBREL generated $3.70 B in revenue, representing 13.11% of its total revenue.
  • Evenity generated $1.16 B in revenue, representing 4.11% of its total revenue.
  • KRYSTEXXA generated $272.00 M in revenue, representing 0.96% of its total revenue.
  • Kyprolis generated $1.40 B in revenue, representing 4.98% of its total revenue.
  • Nplate generated $1.48 B in revenue, representing 5.24% of its total revenue.
  • Otezla generated $2.19 B in revenue, representing 7.76% of its total revenue.
  • Other Products generated $5.26 B in revenue, representing 18.67% of its total revenue.
  • Product and Service, Other generated $1.28 B in revenue, representing 4.54% of its total revenue.
  • Prolia generated $4.05 B in revenue, representing 14.36% of its total revenue.
  • Repatha (evolocumab) generated $1.64 B in revenue, representing 5.8% of its total revenue.
  • TEPEZZA generated $448.00 M in revenue, representing 1.59% of its total revenue.
  • Vectibix generated $984.00 M in revenue, representing 3.49% of its total revenue.
  • XGEVA generated $2.11 B in revenue, representing 7.49% of its total revenue.

The biggest segment for Amgen is the Other Products, which represents 18.67% of its total revenue.
The smallest segment for Amgen is the KRYSTEXXA, which represents 0.96% of its total revenue.

The above chart shows Amgen's revenue percentage share by segment (products and services).

In fiscal year 2024, Amgen's revenue by segment is as follows:

  • Aranesp generated $1.34 B in revenue, representing 4.02% of its total revenue.
  • BLINCYTO generated $1.22 B in revenue, representing 3.64% of its total revenue.
  • ENBREL generated $3.32 B in revenue, representing 9.92% of its total revenue.
  • EVENITY generated $1.56 B in revenue, representing 4.68% of its total revenue.
  • KRYSTEXXA generated $1.19 B in revenue, representing 3.55% of its total revenue.
  • Kyprolis generated $1.50 B in revenue, representing 4.5% of its total revenue.
  • Nplate generated $1.46 B in revenue, representing 4.36% of its total revenue.
  • Otezla generated $2.13 B in revenue, representing 6.36% of its total revenue.
  • Other Products generated $5.63 B in revenue, representing 16.84% of its total revenue.
  • Product and Service, Other generated $1.40 B in revenue, representing 4.18% of its total revenue.
  • Prolia generated $4.37 B in revenue, representing 13.09% of its total revenue.
  • Repatha (evolocumab) generated $2.22 B in revenue, representing 6.65% of its total revenue.
  • TEPEZZA generated $1.85 B in revenue, representing 5.54% of its total revenue.
  • TEZSPIRE generated $972.00 M in revenue, representing 2.91% of its total revenue.
  • Vectibix generated $1.05 B in revenue, representing 3.13% of its total revenue.
  • XGEVA generated $2.23 B in revenue, representing 6.66% of its total revenue.

The biggest segment for Amgen is the Other Products, which represents 16.84% of its total revenue.
The smallest segment for Amgen is the TEZSPIRE, which represents 2.91% of its total revenue.

The above chart shows Amgen's revenue percentage share by segment (products and services).

In fiscal year 2025, Amgen's revenue by segment is as follows:

  • Aranesp generated $1.39 B in revenue, representing 3.93% of its total revenue.
  • BLINCYTO generated $1.56 B in revenue, representing 4.41% of its total revenue.
  • ENBREL generated $2.23 B in revenue, representing 6.3% of its total revenue.
  • EVENITY generated $2.10 B in revenue, representing 5.94% of its total revenue.
  • KRYSTEXXA generated $1.34 B in revenue, representing 3.79% of its total revenue.
  • Nplate generated $1.52 B in revenue, representing 4.31% of its total revenue.
  • Otezla generated $2.27 B in revenue, representing 6.41% of its total revenue.
  • Other Products generated $7.26 B in revenue, representing 20.55% of its total revenue.
  • Product and Service, Other generated $1.60 B in revenue, representing 4.54% of its total revenue.
  • Prolia generated $4.41 B in revenue, representing 12.49% of its total revenue.
  • Repatha generated $3.02 B in revenue, representing 8.53% of its total revenue.
  • TEPEZZA generated $1.90 B in revenue, representing 5.38% of its total revenue.
  • TEZSPIRE generated $1.48 B in revenue, representing 4.18% of its total revenue.
  • Vectibix generated $1.18 B in revenue, representing 3.32% of its total revenue.
  • XGEVA generated $2.08 B in revenue, representing 5.9% of its total revenue.

The biggest segment for Amgen is the Other Products, which represents 20.55% of its total revenue.
The smallest segment for Amgen is the Vectibix, which represents 3.32% of its total revenue.
Continue reading...

Summary Table

Products & Services (Percent Share) 2023 2024 2025
Repatha (evolocumab) 5.8% 6.65% -
Prolia 14.36% 13.09% 12.49%
Product and Service, Other 4.54% 4.18% 4.54%
Other Products 18.67% 16.84% 20.55%
Otezla 7.76% 6.36% 6.41%
Nplate 5.24% 4.36% 4.31%
Kyprolis 4.98% 4.5% -
KRYSTEXXA 0.96% 3.55% 3.79%
Evenity 4.11% - -
ENBREL 13.11% 9.92% 6.3%
BLINCYTO 3.05% 3.64% 4.41%
Aranesp 4.83% 4.02% 3.93%
TEPEZZA 1.59% 5.54% 5.38%
Vectibix 3.49% 3.13% 3.32%
XGEVA 7.49% 6.66% 5.9%
EVENITY - 4.68% 5.94%
TEZSPIRE - 2.91% 4.18%
Repatha - - 8.53%
Total Revenue 100% 100% 100%

The above chart shows the revenue trend of different segments of Amgen.

In fiscal year 2025, the Other Products generated the most revenue ($7.26 B), and the Vectibix generated the least revenue ($1.18 B).

The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Aranesp revenue increased 3.5% ($47.00 M) from $1.34 B (in 2024) to $1.39 B (in 2025).
  • BLINCYTO revenue increased 28.21% ($343.00 M) from $1.22 B (in 2024) to $1.56 B (in 2025).
  • ENBREL revenue decreased -32.87% ($1.09 B) from $3.32 B (in 2024) to $2.23 B (in 2025).
  • EVENITY revenue increased 34.36% ($537.00 M) from $1.56 B (in 2024) to $2.10 B (in 2025).
  • KRYSTEXXA revenue increased 13.08% ($155.00 M) from $1.19 B (in 2024) to $1.34 B (in 2025).
  • Kyprolis revenue decreased -100% ($1.50 B) from $1.50 B (in 2024) to $0.00 (in 2025).
  • Nplate revenue increased 4.67% ($68.00 M) from $1.46 B (in 2024) to $1.52 B (in 2025).
  • Otezla revenue increased 6.54% ($139.00 M) from $2.13 B (in 2024) to $2.27 B (in 2025).
  • Other Products revenue increased 29.01% ($1.63 B) from $5.63 B (in 2024) to $7.26 B (in 2025).
  • Product and Service, Other revenue increased 14.66% ($205.00 M) from $1.40 B (in 2024) to $1.60 B (in 2025).
  • Prolia revenue increased 0.91% ($40.00 M) from $4.37 B (in 2024) to $4.41 B (in 2025).
  • Repatha revenue increased 100% ($3.02 B) from $0.00 (in 2024) to $3.02 B (in 2025).
  • Repatha (evolocumab) revenue decreased -100% ($2.22 B) from $2.22 B (in 2024) to $0.00 (in 2025).
  • TEPEZZA revenue increased 2.81% ($52.00 M) from $1.85 B (in 2024) to $1.90 B (in 2025).
  • TEZSPIRE revenue increased 52.06% ($506.00 M) from $972.00 M (in 2024) to $1.48 B (in 2025).
  • Vectibix revenue increased 12.44% ($130.00 M) from $1.05 B (in 2024) to $1.18 B (in 2025).
  • XGEVA revenue decreased -6.34% ($141.00 M) from $2.23 B (in 2024) to $2.08 B (in 2025).
    • Continue reading...

    Summary Table

    Products & Services 2023
    Value Change
    		2024
    Value Change
    		2025
    Value Change
    Aranesp $1.36 B - $1.34 B
    1.47%
    		$1.39 B
    3.50%
    BLINCYTO $861.00 M - $1.22 B
    41.23%
    		$1.56 B
    28.21%
    ENBREL $3.70 B - $3.32 B
    10.31%
    		$2.23 B
    32.87%
    Evenity $1.16 B - - - - -
    EVENITY - - $1.56 B - $2.10 B
    34.36%
    KRYSTEXXA $272.00 M - $1.19 B
    335.66%
    		$1.34 B
    13.08%
    Kyprolis $1.40 B - $1.50 B
    7.13%
    		- -
    Nplate $1.48 B - $1.46 B
    1.42%
    		$1.52 B
    4.67%
    Otezla $2.19 B - $2.13 B
    2.83%
    		$2.27 B
    6.54%
    Other Products $5.26 B - $5.63 B
    6.97%
    		$7.26 B
    29.01%
    Product and Service, Other $1.28 B - $1.40 B
    9.22%
    		$1.60 B
    14.66%
    Prolia $4.05 B - $4.37 B
    8.05%
    		$4.41 B
    0.91%
    Repatha - - - - $3.02 B -
    Repatha (evolocumab) $1.64 B - $2.22 B
    35.90%
    		- -
    TEPEZZA $448.00 M - $1.85 B
    313.17%
    		$1.90 B
    2.81%
    TEZSPIRE - - $972.00 M - $1.48 B
    52.06%
    Vectibix $984.00 M - $1.05 B
    6.20%
    		$1.18 B
    12.44%
    XGEVA $2.11 B - $2.23 B
    5.35%
    		$2.08 B
    6.34%
    Total Revenue $28.19 B - $33.42 B
    18.57%
    		$36.75 B
    9.95%

    Frequently Asked Questions

    What was Amgen's largest product segment last year?

    In fiscal year 2025, Other Products revenue reached $7.26 Billion, representing 20.55% of Amgen's total revenue and making it the largest segment for the company.

    Which product segment experienced the highest growth for Amgen last year?

    The TEZSPIRE segment is Amgen's highest growth segment, with a revenue growth of +52.06% in 2025 compared to 2024.

    Related company

    Submit feedback to Bullfincher